Key clinical point: High levels of dihydrotestosterone (DHT) are associated with a reduced risk of long-term prostate cancer mortality.

Major finding: High DHT levels correlated with better prostate cancer-specific survival (hazard ratio [HR], 0.44; 95% confidence interval, 0.25‐0.77). In the sub-group analysis, a correlation was seen in men without any clinical signs of prostate cancer (HR, 0.25; 95% confidence interval, 0.07-0.88) and in men with a prostate cancer diagnosis at the time of inclusion in the study (HR, 0.50; 95% confidence interval, 0.26-0.94).

Study details: The data come from a study of 65 men diagnosed with prostate cancer and 130 control participants without any signs of prostate cancer.

Disclosures: No study sponsor was identified.